Back to Search
KEITH FLAHERTY, MD
MD
Specialist
NPI: 1861422966IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
241789(MA)
Education
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Class of 1997
Research & Publications (20)
A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States).
PMID 16184476·Cancer Causes Control·2005
8-other
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
PMID 16507217·Curr Oncol Rep·2006
6-review
Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer.
PMID 15057152·Am J Clin Oncol·2004
3-trial
Cigarette smoking in interstitial lung disease: concepts for the internist.
PMID 15464118·Med Clin North Am·2004
6-review
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?
PMID 15256390·Am J Respir Crit Care Med·2004
8-other
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
PMID 12811513·Cancer Chemother Pharmacol·2003
3-trial
Drug targeting of oncogenic pathways in melanoma.
PMID 19464605·Hematol Oncol Clin North Am·2009
6-review
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.
PMID 19549767·Clin Cancer Res·2009
8-other
Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis.
PMID 19151189·Am J Respir Crit Care Med·2009
7-preclinical
Preclinical and clinical development of targeted therapy in melanoma: attention to schedule.
PMID 19619259·Pigment Cell Melanoma Res·2009
8-other
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
PMID 19351826·Cancer Res·2009
6-review
Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis.
PMID 19179488·Am J Respir Crit Care Med·2009
8-other
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
PMID 19188183·Clin Cancer Res·2009
3-trial
Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
PMID 19156138·Br J Cancer·2009
6-review
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008.
PMID 19659612·Pigment Cell Melanoma Res·2009
8-other
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
PMID 19663727·Future Oncol·2009
7-preclinical
Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
PMID 19401062·J Natl Compr Canc Netw·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 55 FRUIT ST, LAWRENCE HOUSE 202
BOSTON, MA 02114 - Phone
- (617) 643-5817
Quick Facts
- NPI
- 1861422966
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 20
Are you this provider?
Claim Your Profile